

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

BECOMING A CONSTITUENT OF THE HANG SENG FAMILY OF INDEXES

Ascentage Pharma Group International (the “**Company**” or “**Ascentage Pharma**”) is pleased to announce that the Company has been selected as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from September 7, 2020:

- 1) Hang Seng Composite Index ;
- 2) Hang Seng Hong Kong-Listed Biotech Index; and
- 3) Hang Seng Healthcare Index.

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalisation of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Adopting the freefloat-adjusted market capitalisation methodology, the Hang Seng Composite Index can be used as a basis for index funds, mutual funds as well as performance benchmarks. The Hang Seng Hong Kong-Listed Biotech Index reflects the overall performance of the biotech companies that are listed in Hong Kong, including stocks listed on the Stock Exchange through Chapter 18A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The Hang Seng Healthcare Index aims to reflect the overall performance of stocks listed in Hong Kong that are related to healthcare businesses.

The board of directors of the Company (the “**Board**”) is of the view that the selection of the Company as a constituent stock of the abovementioned index series of Hang Seng Indexes Company Limited represents the capital market’s recognition of and confidence in the Company’s business, stock liquidity and development prospects. Additionally, it is expected to be conducive in introducing more diversified investors for the Company and to promote the Company’s reputation in the capital market.

Leveraging our core competency in research and development as well as operation, Ascentage Pharma will continue to seize the major opportunities in the development of the biopharmaceuticals industry. Furthermore, we are committed to providing safe and effective treatment options for global patients and endeavor to create value for shareholders.

Please visit the website of Hang Seng Indexes Company Limited (<http://www.hsi.com.hk>) for the relevant press release and index notice.

By order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, August 17, 2020

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng, Dr. Tian Yuan, Mr. Zhao Qun, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng and Mr. Ren Wei as independent non-executive Directors.